Top Markets
#1 ONFA ONFA +217.91%
#2 Resolv wstUSR Resolv wstUSR +198.08%
#3 Noon Noon +41.33%
#4 Doge Strategy Doge Strategy +38.28%
#5 DeAgentAI DeAgentAI +36.64%
#6 NKN NKN +34.87%
#7 StakeStone StakeStone +29.44%
#8 BLOCKv BLOCKv +25.50%
#9 KONET KONET +24.76%
#10 OpenVPP OpenVPP +21.34%
Coin of the day
ONFA ONFA
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Ensysce Biosciences, Inc. Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc.

ENSC
Classificação em ações #19706
Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in... Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.
Preço da ação
$0.5275
Valor de mercado
$1.25M
Variação (1 dia)
-3.56%
Variação (1 ano)
-83.77%
País
US
Negociar Ensysce Biosciences, Inc. (ENSC)

Categoria

Healthcare
Margem Operacional de Ensysce Biosciences, Inc. (ENSC)
Margem Operacional em March 2026 TTM: -245.89%
De acordo com os relatórios financeiros mais recentes e o preço das ações da Ensysce Biosciences, Inc., a margem operacional atual (TTM) é -245.89%. No final de 2023, a margem operacional era -480.41%.
Histórico da Margem Operacional da Ensysce Biosciences, Inc. de 2017 a 2026
Margem Operacional no final de cada ano
Ano Margem Operacional Alterar
2026 (TTM) -245.89% 90.36%
2024 -129.17% -73.11%
2023 -480.41% -49.96%
2022 -960.05% 70.61%
2021 -562.73% 1,271.51%
2020 -41.03% -78.26%
2019 -188.72% 0.00%
2018 0.00% 0.00%
2017 0.00% 0.00%
Margem Operacional de empresas semelhantes ou concorrentes
Empresa Margem Operacional Diferença na Margem Operacional País
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
41.30% -100.17%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
35.45% -100.14%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
24.95% -100.10%
US
UCB SA UCB SA
UCB SA
UCB.BR
25.32% -100.10%
BE
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -100.10%
AU
O que é a Margem Operacional de uma empresa?
A Margem Operacional é um indicador essencial para avaliar a rentabilidade de uma empresa. Margens operacionais mais altas geralmente são melhores, pois mostram que uma empresa consegue vender seus produtos ou serviços por muito mais do que o custo de produzi-los. É calculada dividindo os lucros da empresa pela sua receita.